The tweet was deleted by the author.
But we saved everything 🙂.
Anika Therapeutics is prioritizing pain treatment for osteoarthritis through its hyaluronic acid-based injection therapies.
The company announced that Orthovisc and Monovisc are available in the U.S. as a result of distribution by J&J Medtech, while Cingal is currently not offered in the U.S. Anika Therapeutics has focused on these therapies for decades to address chronic pain among osteoarthritis patients. The partnership with J&J Medtech expands access to Anika Therapeutics' therapies within the U.S. healthcare market.
Anika Therapeutics recently released a case report on its Integrity implant, which showed superior outcomes in a high-risk rotator cuff patient compared to standard repair. The company has a history of developing therapies targeting musculoskeletal conditions. Previous disclosures have focused on clinical results from innovative products in orthopedics.